We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
With the last legal hurdle removed, Sandoz wasted no time launching its Zarxio biosimilar of Amgen’s chemotherapy product Neupogen nationwide — offering the first U.S. biosimilar at 15 percent below the price of its reference product. Read More
Sanofi will terminate its 19-month collaboration with Ardelyx, effective Sept. 30, ending an alliance that focused on developing NaP2b phosphate inhibitors for kidney disease. Read More
Sanofi will terminate its 19-month collaboration with Ardelyx, effective Sept. 30, ending an alliance that focused on developing NaP2b phosphate inhibitors for kidney disease. Read More
Acadia Pharmaceuticals Wednesday filed an NDA with the FDA for Nuplazid, a product that, if approved, would be a first-in-class drug and the first specific treatment for Parkinson’s disease psychosis. Read More
Amgen and Novartis have launched a neuroscience drug collaboration to develop and commercialize new inhibitors to fight Alzheimer’s disease and treat migraines. Read More
The FDA has approved Merck’s anti-nausea and vomiting drug Emend for children undergoing chemotherapy, making the drug the first and only NK1 receptor antagonist for this indication. Read More
Leaders of the House Energy & Commerce Committee are asking FDA Acting Commissioner Stephen Ostroff to explain what steps the agency is taking to address safety concerns around the blood thinner Coumadin and its generic version, warfarin. Read More